SCHEMBL488809

SCHEMBL488809

Fc1ccc(F)c(COc2cncc(-c3ccccc3)c2)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.45
CHRNA4 P43681 1/20 0.45
INPPL1 O15357 9/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CHRNB1 P11230 2/20 0.41
CHRNB4 P30926 2/20 0.41
CHRNA3 P32297 2/20 0.41
CHRNB3 Q05901 2/20 0.41
MET P08581 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL488537 0.82 CHRNB2 (0.43) CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3
2-Aminopyridine SCHEMBL27630019 0.78 MEN1 (0.49) MEN1KMT2AMET
SCHEMBL487679 0.77 MET (0.57) MET
SCHEMBL10215935 0.72 MAP4K4 (0.44) MET
SCHEMBL30453168 0.71 JAK2 (0.60) METCYP11B1CYP11B2
SCHEMBL4639245 0.71 MAOB (0.51) MEN1KMT2A
SCHEMBL30423385 0.70 CYP11B1 (0.59) CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3
SCHEMBL30452799 0.68 MET (0.52) MET
SCHEMBL488590 0.68 JAK2 (0.51) INPPL1MET
SCHEMBL5583002 0.68 MAPK1 (0.56) CHRNB2CHRNA4MEN1KMT2ACHRNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 CHRNB2 4036/4885CHRNA4 4469/4885INPPL1 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.